| Excerpt | Reference |
|---|
| "Immune thrombocytopenic purpura is a relatively common disease that occurs in both pediatric and adult populations." | ( Kirchner, JT, 1992) |
| "Chronic idiopathic thrombocytopenic purpura is a destructive thrombocytopenia caused by an autoantibody." | ( Figueroa, M; Gehlsen, J; Hammond, D; McMillan, R; Ondreyco, S; Piro, L; Pomeroy, T; Williams, F, 1993) |
| "Autoimmune thrombocytopenic purpura is a common disease during pregnancy." | ( Gross, Z; Rodriguez, JJ; Stalnaker, BL, 1995) |
| "Immune thrombocytopenic purpura is rarely reported in association with inflammatory bowel disease." | ( Ammirati, M; Gruenstein, S; Kim, P; Korelitz, BI; Lipsey, L; Schwarz, S; Wisch, N; Zlatanic, J, 1997) |
| "Autoimmune thrombocytopenia is generally caused by autoantibodies against glycoprotein (GP) IIb-IIIa or GPIb-IX and occasionally against GPIa-IIa or GPV." | ( Campbell, K; Dong, JF; Garner, SF; Huiskes, E; Keidan, J; López, JA; Metcalfe, P; Ouwehand, WH, 2002) |
| "Immune thrombocytopenia is also reported in brucellosis, resulting usually in massive thrombocytopenia, purpura, and spontaneous hemorrhage." | ( Christou, L; Kitsanou, M; Pappas, G; Tsianos, E, 2004) |
| "Idiopathic thrombocytopenic purpura is an autoimmune disease which involves opsonization of platelets by autoantibodies directed against different surface glycoproteins, leading to their premature destruction by the reticuloendothelial system." | ( Andersen, I; Andersen, TM; Birgens, HS; Bjerrum, OW; Braendstrup, P; Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Nielsen, OJ; Pedersen, BB; Peterslund, NA; Plesner, T; Schmidt, K, 2005) |
| "Idiopathic thrombocytopenic purpura is an acquired disease characterised by a low platelet count." | ( Nurden, AT; Nurden, P; Viallard, JF, 2009) |
| "Idiopathic thrombocytopenic purpura is an autoimmune disorder characterized by a low platelet count." | ( Borras, R; Cambray, C; Jamart, V; Mailan, J; Raynard Ortiz, M, 2009) |
| "Immune thrombocytopenia is a disease mediated by platelet autoantibodies that accelerate platelet destruction and inhibit their production." | ( Allegra, A; Alonci, A; D'Angelo, A; Granata, A; Musolino, C; Penna, G, 2010) |
| "Primary immune thrombocytopenia is an acquired autoimmune disorder characterized by platelet count of <100 × 10(9)/l in the absence of other causes of thrombocytopenia." | ( Arabadjief, M; Boiocchi, L; Bussel, JB; Geyer, JT; Ghanima, W; Orazi, A, 2012) |
| "Primary immune thrombocytopenia is a potentially life-threatening condition." | ( Gooneratne, L; Rodrigo, C, 2013) |
| "Autoimmune thrombocytopenic purpura is an immunological disorder characterized by increased platelet destruction due to presence of anti-platelet autoantibodies." | ( Lebano, R; Masarone, M; Persico, M; Romano, M; Rosato, V, 2014) |
| "Autoimmune thrombocytopenia is an uncommon but reported paraneoplastic manifestation of renal cell carcinoma (RCC)." | ( Chan, H; Epstein, RJ; Joseph, JE; Zheng, S, 2015) |
| "Primary immune thrombocytopenia is a severe bleeding disorder." | ( Feng, FE; Feng, R; Hou, M; Huang, XJ; Jiang, H; Jiang, Q; Liu, H; Liu, KY; Lu, J; Peng, J; Shen, JL; Wang, JW; Wang, M; Xu, LP; Zhang, JM; Zhang, XH, 2017) |
| "Immune thrombocytopenia is an unpredictable disease." | ( Kiss, C; Kovács, G, 2017) |
| "Primary immune thrombocytopenia is an autoimmune disease, characterized with decreased platelet and increased risk of bleeding." | ( Chen, H; Cheng, L; Cheng, Y; Ji, L; Ke, Y; Li, F; Liu, C; Lu, Y; Min, Z; Shao, X; Sun, L; Wu, B; Zhan, Y, 2019) |
| "Immune thrombocytopenia is an autoimmune disorder characterised by autoantibody production against platelets, increased platelet destruction and impaired thrombopoiesis." | ( Dalal, P; Gulia, M; Gupta, M; Tahlan, A, 2019) |
| "Patients with immune thrombocytopenia are at risk of both bleeding complications and venous thromboembolism." | ( Brodsky, RA; Haines, C; Hui, C, 2020) |
| "Primary immune thrombocytopenia is an autoimmune bleeding disorder." | ( Han, P; Hou, M; Hou, Y; Li, D; Liu, X; Peng, J; Qiu, J; Shao, L; Sun, L; Wang, J; Wang, Z; Xu, M; Yu, Y; Yuan, C; Zhao, H; Zhou, H, 2021) |
| "Immune thrombocytopenia is a haematological, autoimmune disorder characterized by elevated platelet demolition due to the presence of antiplatelet autoantibodies derived from B cells and to an irregular, deficient process of platelets production in bone marrow." | ( Allegra, A; Caserta, S; Innao, V; Musolino, C; Zaccuri, AM, 2021) |
| "Immune thrombocytopenia is a rare autoimmune disorder with associated bleeding risk and fatigue." | ( Bagot, C; Bradbury, CA; Breheny, K; Cooper, N; Evans, G; Greenwood, R; Hill, Q; Ingram, J; Kandiyali, R; Pell, J; Rayment, R; Talks, K; Thomas, I, 2021) |
| "Drug-induced immune thrombocytopenia is an isolated thrombocytopenia caused by accelerated platelet destruction from drug-dependent, platelet-reactive antibodies." | ( Kiliaki, S, 2023) |
| "Immune thrombocytopenic purpura is a condition associated with an unusual, unexplained, and sometimes very severe reduction in the level of platelets in the blood." | ( Agyapong, KO; Bampoh, SA; Fiador, K; Fiscian, H; Folson, AA; Kootin-Sanwu, C; Tufuor, M; Wonkyi, R, 2023) |
| Excerpt | Reference |
|---|
| "Eight patients with severe chronic autoimmune thrombocytopenic purpura (AITP) refractory to high-dose intravenous immunoglobulin (IVIgG) and/or oral prednisone were treated with one to three infusions of high-dose methylprednisolone (HDMP) (15 mg/kg/day)." | ( Bierling, P; Godeau, B; Schaeffer, A; Zini, JM, 1995) |
| "She has been under treatment for idiopathic thrombocytopenic purpura (ITP) with prednisolone for these last 14 years." | ( Hirokawa, M; Ikeda, I; Masuda, M; Nakagomi, K; Terao, T, 1993) |
| "In childhood idiopathic thrombocytopenic purpura (ITP), both intravenous high-dose steroids and immunoglobulin treatments have been demonstrated to raise platelet counts reliably and in most cases within 72 h, when used as separate therapeutic modalities." | ( Barrios, NJ; Humbert, JR; McNeil, J, 1993) |
| "A 63-year-old female with chronic idiopathic thrombocytopenic purpura refractory to prednisolone therapy was treated with interferon alpha-2b (IFN alpha-2b)." | ( Hirano, H; Kanazawa, T; Kuriya, S; Miyairi, Y; Murai, K; Narigasawa, Y; Takeda, R; Utsugisawa, T, 1993) |
| "However, 17% of patients with immune thrombocytopenia had reticulated platelet values in the range observed for normal subjects and for patients with chemotherapy." | ( Ault, KA; Bonan, JL; Munz, UJ; Rinder, HM; Smith, BR, 1993) |
| "A history of idiopathic thrombocytopenic purpura could be considered a contraindication for alpha-interferon therapy in patients with chronic viral hepatitis." | ( Bacq, Y; Barin, F; Degenne, D; Fimbel, B; Gruel, Y; Metman, EH; Sapey, T, 1996) |
| "Most patients with chronic idiopathic thrombocytopenic purpura (TTP) show a good initial response to treatment with corticosteroids." | ( Ben-Tal, O; Bulvik, S; Eldor, A; Shimoni, Z, 1996) |
| "Sixty-six adults with chronic autoimmune thrombocytopenic purpura AITP and platelet count <50 x 10(9)/l were treated with dapsone (75-100 mg orally)." | ( Bierling, P; Durand, JM; Godeau, B; Kaplanski, G; Oksenhendler, E; Roudot-Thoraval, F; Schaeffer, A; Tennezé, A, 1997) |
| "The article studied 61 patients with idiopathic thrombocytopenic purpura, they were classified and treated with Chinese herbal medicine Zhinu (ZN) -I, -II, in comparison with 30 cases of patients treated with prednisone." | ( Hong, F; Yang, YQ; Zeng, FC, 1996) |
| "A 14-month-old boy with refractory idiopathic thrombocytopenic purpura (ITP), who was successfully treated with pulsed high-dose oral dexamethasone therapy is reported." | ( Kakihara, T; Kataoka, S; Okada, R; Tanaka, A; Uchiyama, M; Watanabe, A; Yamamoto, K, 1997) |
| "We report a case of refractory idiopathic thrombocytopenic purpura successfully treated with pulsed high-dose oral dexamethasone, which offered ease of administration, low cost, and low risk." | ( Byrne, JD; Goodwin, TM; Incerpi, MH, 1997) |
| "Ten adult patient of chronic idiopathic thrombocytopenic purpura (CITP) used oral prednisone and were treated with seven doses of oral high-dose methylprednisolone (30 mg/kg)." | ( Albayrak, D; Altintop, L, 1997) |
| "Fifty-seven adult patients with idiopathic thrombocytopenic purpura (ITP) were treated with either conventional-dose prednisolone (CDP) (1 mg/kg/d, 36 patients) or high-dose methylprednisolone (HDP) (30 mg/kg/d, 21 patients), as first-line treatment." | ( Akoglu, T; Alpdogan, O; Bayik, M; Budak-Alpdogan, T; Firatli-Tuglular, T; Karti, S; Ratip, S; Tanriverdi, S, 1998) |
| "We describe two cases of autoimmune thrombocytopenia precipitated by fludarabine therapy in patients with chronic lymphatic leukaemia." | ( Leach, M; Parsons, RM; Reilly, JT; Winfield, DA, 2000) |
| "A 69-year-old woman with idiopathic thrombocytopenic purpura, who was regularly followed and treated with prednisolone and danazol, was admitted to our hospital because of shortness of breath." | ( Abe, Y; Ando, T; Ashizawa, K; Eguchi, K; Ejima, E; Ide, A; Nakata, K; Sera, N; Tominaga, T; Usa, T, 2001) |
| "Patients with refractory autoimmune thrombocytopenia do not respond to standard therapy with high-dose corticosteroids, intravenous immunoglobulin, and splenectomy." | ( Baruchel, S; Cividalli, G; Freeman, A; Gesundheit, B; Koren, G; Yatziv, S, 2001) |
| "Patients with chronic immune thrombocytopenic purpura (ITP) who are unresponsive to corticosteroids require splenectomy, but if this fails, treatment is difficult." | ( Kappers-Klunne, MC; van't Veer, MB, 2001) |
| "Treatment of adults with autoimmune thrombocytopenic purpura (AITP) is based more on individual experience than on results of controlled studies." | ( Bassompierre, F; Bierling, P; Chevret, S; Chèze, S; Fain, O; Godeau, B; Grange, MJ; Hulin, C; Lefrère, F; Legouffe, E; Varet, B; Zini, JM, 2002) |
| "Treatment of severe, chronic idiopathic thrombocytopenic purpura (ITP) refractory to most usual therapies is a difficult challenge." | ( Bertesi, M; D'Apollo, N; Emilia, G; Ferrara, L; Gandini, G; Longo, G; Luppi, M; Marasca, R; Morselli, M; Potenza, L; Torelli, G, 2002) |
| "We herewith report a case of SJS with idiopathic thrombocytopenic purpura (ITP) that did not respond to daily oral prednisolone therapy." | ( Agarwalla, A; Agrawal, S; Barman, KD; Rijal, A; Verma, KK, 2003) |
| "To report a case of autoimmune thrombocytopenia due to chronic lymphocytic leukemia (CLL) treated with fludarabine." | ( Kovacs, MJ; Wells, T, 2003) |
| "The treatment of chronic idiopathic thrombocytopenic purpura (ITP) is difficult in those unresponsive to corticosteroids and/or splenectomy." | ( Hou, M; Ji, X; Peng, J; Qin, P; Shi, Y; Wang, X; Zhang, C; Zhang, M; Zhao, C, 2003) |
| "Treatment of immune thrombocytopenic purpura (ITP) includes agents that are substrates of P-gp; hence, the objective of this study was to analyze the functional activity of P-gp in lymphocytes from patients with ITP." | ( Llorente, L; López-Karpovitch, X; Richaud-Patin, Y; Ruiz-Soto, R, 2003) |
| "We successfully treated three idiopathic thrombocytopenic purpura (ITP) patients with clarithromycin (CAM)." | ( Kohno, M; Ohe, M, 2003) |
| "Adults with chronic idiopathic thrombocytopenic purpura (ITP) in whom standard-dose corticosteroids and splenectomy have failed or who have contraindications to these therapies often require further treatment for life-threatening thrombocytopenia or bleeding." | ( Andrès, E; Dufour, P; Koumarianou, A; Maloisel, F; Noel, E; Zamfir, A; Zimmer, J, 2004) |
| "We present two cases of chronic idiopathic thrombocytopenic purpura (ITP) on prolonged steroid therapy who developed subcutaneous and brain abscesses due to Nocardia asteroides." | ( Agarwal, V; Dabadghao, S; Nityanand, S; Prasad, KN; Wakhlu, A, 2004) |
| "Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow." | ( Aster, RH; Blank, J; Curtis, BR; Kaliszewski, J; Marques, MB; McFarland, JG; Nabelle, L; Saif, MW, 2006) |
| "The treatment of autoimmune thrombocytopenic purpura (AITP) remains unsatisfactory in patients refractory to first-line management such as corticosteroid therapy and/or splenectomy." | ( Cernelc, P; Zupan, IP; Zver, S, 2006) |
| "Nevertheless, rare cases of autoimmune thrombocytopenia following standard or pegylated interferon treatment have been reported in the literature." | ( Aslan, V; Aykin, N; Cevik, F; Demirdal, T; Demirturk, N, 2006) |
| "Recurrent immune thrombocytopenic purpura (ITP) is defined as the recurrence of ITP after at least 3 months of remission sustained without treatment." | ( Jayabose, S; Levendoglu-Tugal, O; Ozkaynak, MF; Sandoval, C, 2006) |
| "The patient treated for autoimmune thrombocytopenia had a favorable response, with no relapses, and creatine-kinase levels also tended to return to normal." | ( Castillo Palma, MJ; Colorado Bonilla, R; García Hernández, FJ; Garrido Rasco, R; González León, R; Ocaña Medina, C; Sánchez Román, J, 2007) |
| "Patients with severe immune thrombocytopenic purpura (ITP) may require an acute increase in the platelet count for surgery or ongoing hemorrhage as well as long-term maintenance treatment." | ( Boruchov, DM; Bussel, JB; Driscoll, MC; Gururangan, S, 2007) |
| "The treatment landscape of immune thrombocytopenic purpura has the potential for dramatic change in the near future as promising new agents and adaptations of older therapies enter clinical study." | ( Andemariam, B; Bussel, J, 2007) |
| "Patients with chronic immune thrombocytopenic purpura (ITP) only require treatment if they are bleeding, or prior to scheduled operations." | ( Panzer, S, 2008) |
| "Various agents to treat immune thrombocytopenic purpura (ITP) have been developed on the principle that stimulating the thrombopoietin (TPO) receptor would increase platelet production." | ( Kuter, DJ, 2008) |
| "Therapy in refractory chronic idiopathic thrombocytopenic purpura is usually a difficult and expensive procedure, with little benefit to the patient, and the results are typically only short-term improvements." | ( Arat, M; Arslan, O; Ilhan, O; Konuk, N; Ozcan, M; Soydan, E; Yazman, D, 2008) |
| "In adults with immune thrombocytopenic purpura (ITP), steroids are usually proposed as first-line therapy, but long-term complete responses are obtained in no more than 20% of patients." | ( Annichino-Bizzacchi, JM; De Paula, EV; Fabri, DR; Orsi, FL; Ozelo, MC; Vancine-Califani, SM, 2008) |
| "Some infants with acute immune thrombocytopenic purpura (ITP) do not respond to first-line therapy, and currently there is no consensus on therapy for these refractory cases." | ( Hatakeyama, N; Hori, T; Iesato, K; Inazawa, N; Suzuki, N; Tsutsumi, H; Yamamoto, M, 2009) |
| "Treatment modalities for chronic idiopathic thrombocytopenic purpura (ITP) are numerous, but the response is variable, often disappointing and associated with high risks." | ( Panzer, S, 2009) |
| "He was diagnosed with acute immune thrombocytopenic purpura 3 months before the admission and treated with high-dose methylprednisolone 2 months ago." | ( Albayrak, D; Atmaca, S; Cetin, R; Duru, F; Fisgin, T; Ozyurek, E, 2009) |
| "The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied on nonspecific immune suppression designed to reduce platelet destruction." | ( Newland, A, 2009) |
| "Patients with primary immune thrombocytopenia (ITP) may require treatment to reduce the risk of serious bleeding if platelets remain consistently below 30 × 10(9)/L." | ( Newland, A; Pabinger, I; Stasi, R; Thornton, P, 2010) |
| "A 71-year-old woman with idiopathic thrombocytopenic purpura (ITP), who had been treated with steroid and cyclosporine, was admitted in an emergency with fever and dyspnea." | ( Akiyama, K; Fukushima, S; Hemmi, A; Horikoshi, A; Kashiwazaki, S; Nakamura, T; Sezai, A; Shiono, M, 2011) |
| "The basis of treatment for immune thrombocytopenia (ITP) has conventionally relied on non-specific immune suppression designed to reduce platelet destruction." | ( Newland, A, 2012) |
| "The therapy for immune thrombocytopenic purpura (ITP) has evolved in the recent past." | ( Aggarwal, S; Randhawa, H; Sharma, A; Sharma, V, 2012) |
| "Patients with immune thrombocytopenia (ITP) may be at increased risk of infection because of the steroids and other immunosuppressive agents used in its treatment." | ( Chen, MH; Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hu, MH; Huang, YC; Liu, CY; Liu, JH; Tzeng, CH; Yu, YB, 2014) |
| "Her major chronic illness was immune thrombocytopenic purpura (ITP) for which she had been treated with prednisone therapy for the past 15 years." | ( Hill, LJ; Tung, EE, 2014) |
| "We describe a case of CLL-associated immune thrombocytopenia (ITP) that had a loss of response to standard treatment for ITP." | ( Jolliffe, E; Romeril, K, 2014) |
| "Two years before she was diagnosed with immune thrombocytopenia, for which she received pulse steroid therapy with high dose of dexamethasone and underwent a splenectomy." | ( Floros, T; Fotopoulos, VCh; Mouzopoulos, G; Tzurbakis, M, 2015) |
| "Primary immune thrombocytopenia (ITP) in adults often assumes a chronic course that requires persistent monitoring and treatment." | ( Cines, DB; Cuker, A; Prak, ET, 2015) |
| "Treatment of refractory immune thrombocytopenia (ITP) continues to challenge medical practitioners because of the lack of well tolerated and effective drugs." | ( Li, AM; Wang, XL, 2016) |
| "Patients aged 1-17 years with immune thrombocytopenia lasting for 6 months or longer and platelets less than 30 × 10(9) per L who had received at least one previous treatment were enrolled." | ( Bailey, CK; Bakshi, KK; Blanchette, VS; Boayue, KB; Bussel, JB; Chagin, KD; Chan, GW; Connor, P; David, M; de Miguel, PG; Despotovic, JM; Grainger, JD; Iyengar, M; Krishnamurti, L; Lambert, MP; Marcello, LM; Matthews, DC; Sevilla, J; Theodore, D, 2015) |
| "Adults often develop chronic immune thrombocytopenia (ITP) for which treatment order is uncertain." | ( Bussel, JB; Chapin, J; Lee, CS; Zehnder, JL; Zhang, H, 2016) |
| "Twenty percent of children with immune thrombocytopenia (ITP) develop a chronic course where treatment strategy is less established." | ( Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY; Lee, AH; Lee, PP; Liu, AP; Tsoi, WC, 2016) |
| "A patient with refractory primary immune thrombocytopenia (ITP) characterised by severe skin and mucosal bleedings was treated with several ITP-directed therapies including cyclophosphamide." | ( Frederiksen, H; Marcher, CW; Mortensen, TB; Preiss, B, 2017) |
| "Drug-induced immune thrombocytopenia should be considered in cases of acute thrombocytopenia in patients undergoing meropenem treatment." | ( Cai, GQ; Gui, R; Huang, R; Liu, FX; Liu, H; Ma, JQ; Nie, XM; Zhang, JH, 2017) |
| "Patients with primary immune thrombocytopenia given ATRA plus danazol had a rapid and sustained response compared with danazol monotherapy." | ( Feng, FE; Feng, R; Hou, M; Huang, XJ; Jiang, H; Jiang, Q; Liu, H; Liu, KY; Lu, J; Peng, J; Shen, JL; Wang, JW; Wang, M; Xu, LP; Zhang, JM; Zhang, XH, 2017) |
| "The clinical significance of immune thrombocytopenia (ITP) is mainly reflected by bleeding and/or bleeding risks, which, in some cases, cannot be adequately controlled by standard therapy." | ( Mayer, B; Salama, A, 2017) |
| "More recent immune thrombocytopenia (ITP) treatment strategies enhance platelet production with the use of thrombopoietin receptor agonists (TPO-RA) such as eltrombopag." | ( Bagai, A; Hashi, A; Sholzberg, M; Taher, A; Teichman, J, 2018) |
| "Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established." | ( Hidaka, M; Hirabayashi, Y; Hishita, T; Iida, H; Ito, T; Iwasaki, H; Kada, A; Nagai, H; Ogata, Y; Otsuka, M; Saito, AM; Sawamura, M; Suehiro, Y; Takafuta, T; Takase, K; Tsutsumi, I; Yoshida, C; Yoshida, I; Yoshida, S; Yoshio, N, 2018) |
| "Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment." | ( Aboud, N; Depré, F; Mayer, B; Salama, A, 2018) |
| "Patients with multirefractory immune thrombocytopenia (ITP) have limited treatment options." | ( Berrueco, R; Campos, RM; Corral, J; de la Morena-Barrio, ME; Fuentes, I; Galvez, E; Gonzalez, N; Gonzalez-Lopez, TJ; Gonzalez-Porras, JR; Lozano, ML; Miñano, A; Mingot-Castellano, ME; Revilla, N; Velasco, F; Vicente, V, 2019) |
| ": The treatment of refractory primary immune thrombocytopenia (RITP) remains challenging because of the lack of well tolerated and effective drugs." | ( Li, A; Liu, X; Wang, JY; Wang, L; Wang, X, 2019) |
| "Persistent immune thrombocytopenia (ITP) patients require second-line treatments, for which information on clinical outcomes are lacking." | ( Attia, J; Ingsathit, A; McEvoy, M; Puavilai, T; Rattanasiri, S; Thadanipon, K; Thakkinstian, A, 2020) |
| "Care of patients with chronic immune thrombocytopenia (ITP) who are refractory to available treatments can be quite challenging." | ( Bussel, JB; Izak, M; Lee, EJ, 2020) |
| "Severe immune thrombocytopenia complicating pregnancy may require treatment beyond first-line medications (intravenous immunoglobulins or corticosteroids), but there is a paucity of literature on the use of such second-line agents in pregnancy." | ( Chan, R; Chon, AH; Kwong, K; Lee, RH; Weitz, IC; Wertheimer, FB, 2020) |
| "Management of immune thrombocytopenia (ITP) during pregnancy can be challenging because treatment choices are limited." | ( Alkindi, S; Bussel, JB; Cheze, S; Ebbo, M; Ghanima, W; Godeau, B; Gonzalez-Lopez, TJ; Michel, M; Ruggeri, M; Terriou, L; Tvedt, THA, 2020) |
| "Tacrolimus-induced immune thrombocytopenia (ITP) is a rare entity that can occur years after initiation of tacrolimus therapy following solid organ transplantation, and platelet recovery can be substantially delayed following discontinuation of tacrolimus." | ( Black, LV; Gipson, DR; Larkin, T; Seifert, R, 2021) |
| "Selection of patients with chronic immune thrombocytopenia from the French national prospective cohort of pediatric autoimmune cytopenia OBS'CEREVANCE and VIGICAIRE study, treated by splenectomy, hydroxychloroquine, azathioprine, or rituximab as a first second-line treatment." | ( Abou Chahla, W; Aladjidi, N; Armari-Alla, C; Barlogis, V; Bayart, S; Bertrand, Y; Cheikh, N; Ducassou, S; Fernandes, H; Guitton, C; Kherfellah, D; Laghouati, S; Leblanc, T; Leverger, G; Pasquet, M; Pellier, I; Savel, H; Thiébaut, R; Thomas, C; Vassal, G, 2021) |
| "Up to 30% immune thrombocytopenia (ITP) patients achieve a sustained remission off-treatment (SROT) after discontinuation of thrombopoietin receptor agonists (TPO-RAs)." | ( Auteri, G; Barcellini, W; Boggio, E; Carli, G; Carpenedo, M; Celli, M; Consoli, U; Crea, E; Dianzani, U; Fanin, R; Giardini, I; Gigliotti, CL; Lucchini, E; Palandri, F; Paoloni, F; Patriarca, A; Rodeghiero, F; Rossi, E; Santoro, C; Valeri, F; Vianelli, N; Vignetti, M; Volpetti, S; Zaja, F, 2021) |
| "The patient had a idiopathic thrombocytopenic purpura complication that required long-term methylprednisolone administration." | ( Li, H; Wang, K; Zhang, X; Zhou, C, 2021) |
| "The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin." | ( AlNajjar, FH; AlRajhi, AM; Howaidi, A; Howaidi, J; Tailor, IK, 2022) |
| "Recommended first-line treatment for immune thrombocytopenia is high-dose glucocorticoids, but side effects, variable responses, and high relapse rates are serious drawbacks." | ( Bagot, C; Bradbury, CA; Breheny, K; Cooper, N; Evans, G; Greenwood, R; Hill, Q; Ingram, J; Kandiyali, R; Pell, J; Rayment, R; Talks, K; Thomas, I, 2021) |
| "Before 4 months, he was diagnosed with immune thrombocytopenia (ITP) and received corticosteroid therapy." | ( Hikosaka, K; Imoto, N; Kurahashi, S; Maeda, M; Norose, K; Omori, K, 2021) |
| "Therapeutic management of patients with immune thrombocytopenia (ITP) remains challenging; however, thrombopoietin receptor agonists (TPO-RAs) have revolutionised the treatment landscape of ITP." | ( Kapur, R, 2022) |
| "In patients with immune thrombocytopenia, fostamatinib administration started at 100 mg twice daily, and most patients increased to 150 mg twice daily in the clinical trial." | ( Hirota, T; Ieiri, I; Matsukane, R; Suetsugu, K, 2022) |
| "Most children treated for immune thrombocytopenia remit during the first year following diagnosis." | ( Goldberg, TA; Levy, CF, 2023) |
| "Differentiating autoimmune thrombocytopenia from thrombocytopenia due to bone marrow infiltration is necessary for appropriate treatment, but sometimes difficult." | ( Honda, A; Jona, M; Kurokawa, M; Maki, H; Masamoto, Y; Morita, K; Nishikawa, M; Oyama, T; Yasunaga, M; Yatomi, Y, 2023) |